EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Video and podcast roundups

Which recorded webinars justify additional specialist time?

Dose Diligence research deskSection 07 · Page 5 of 9Last updated 17 Nov 2026

These three selections are not public YouTube recommendations. They are optional NABP home-study recordings with published $20 activity fees. Credit hours below are CE allocations, not verified playback runtimes. Gated recordings were not reviewed; summaries use official listings and, where available, handouts.

8. How should procurement examine API and testing claims?

Title: A New Regulatory Path for Enforcing GLP-1 Compounding Safety and Protecting Public Health
Access: NABP recording listing

Who and when: Marta Wosińska, PhD; Thomas Kupiec, PhD; Andrew Funk, PharmD; and Susan McCoy, RPh. Recorded May 13, 2026. The listing specifies 1.5 contact hours, a $20 fee, and availability through April 29, 2029. Evidence: organiser-listing-backed. Course details.

Key takeaways supported by the syllabus: The course addresses research-grade active pharmaceutical ingredients, interpretation of API certificates of analysis, and state responses to inappropriate compounding in clinics and med spas. Learning scope. (nabp.pharmacy)

Our procurement application: Have a qualified quality specialist turn a supplier’s testing pack into an evidence register: material identity, lot linkage, test scope, laboratory identity and unanswered questions. Keep the legal eligibility assessment separate.

Limitation: A course about analysing evidence does not verify a particular supplier’s certificate or finished preparation.

9. How should a multi-state clinic evaluate its telemedicine–pharmacy relationship?

Title: Navigating the Regulatory Maze: Telemedicine Compliance and Its Impact on Pharmacies and the Public Health
Access: NABP recording · Public presentation handout

Who and when: Justin Macy, PharmD, JD, NABP director of innovation. Recorded February 13, 2025. The listing specifies one contact hour, a $20 fee, and availability through February 28, 2028. Evidence: listing and handout-backed. Course details.

Key takeaways: The materials connect telemedicine compliance with fulfilment-pharmacy exposure. The handout examines state-specific encounter modalities and business-model features such as bundled consultations and medicine shipments, platform–pharmacy relationships and prescription-contingent refunds. Presentation handout.

Our procurement application: Build a destination-state matrix covering prescriber, encounter model, dispensing entity, product and responsible reviewer. Treat “we serve all states” as a claim requiring evidence.

Limitation: The slides contain historical examples and risk indicators, not a current 50-state legal opinion. Recheck current board material; Ohio’s GLP-1 guidance is one state-specific example, not a national rule.

10. What should happen when medicine provenance looks wrong?

Title: Illicit and Counterfeit Drugs Threaten Americans in the GLP-1 Space
Access: NABP recording · Public presentation handout

Who and when: Shabbir J. Imber Safdar, executive director of the Partnership for Safe Medicines. Recorded August 28, 2025. The listing specifies one contact hour, a $20 fee, and availability through August 28, 2028. Evidence: listing and handout-backed. Course details.

Key takeaways: The course distinguishes threats ranging from unapproved research chemicals to look-alike counterfeits. It covers DSCSA labelling, recognising suspect medicines and procedures for responding to them. Course scope.

Our procurement application: Assign responsibility for preserving packaging and transaction evidence, isolating suspect stock where applicable, contacting the dispensing pharmacy and escalating patient concerns. Have pharmacy and legal specialists determine the route-specific requirements.

Limitation: Do not turn visual packaging checks into proof of authenticity, or apply an approved-product traceability workflow indiscriminately to every compounded preparation.

Sources cited on this page

  1. nabp.pharmacy · Source 1 ↗https://nabp.pharmacy/resource/a-new-regulatory-path-for-enforcing-glp-1-compounding-safety-home-study/
  2. nabp.pharmacy · Source 2 ↗https://nabp.pharmacy/resource/navigating-the-regulatory-maze-telemedicine-compliance-and-its-impact-on-pharmacies-and-the-public-health-home-study/
  3. nabp.pharmacy · Source 3 ↗https://nabp.pharmacy/wp-content/uploads/2025/02/Telehealth-Webinar-Handout-February-13-2025_2.pdf
  4. pharmacy.ohio.gov · Source 4 ↗https://www.pharmacy.ohio.gov/documents/pubs/special/compounding/compounding%20of%20glp-1%20drug%20products%20in%20ohio.pdf
  5. nabp.pharmacy · Source 5 ↗https://nabp.pharmacy/resource/illicit-and-counterfeit-drugs-threaten-americans-in-the-glp-1-space-home-study/
  6. nabp.pharmacy · Source 6 ↗https://nabp.pharmacy/wp-content/uploads/2025/08/Illicit-and-Counterfeit-Drugs-Threaten-Americans-in-the-GLP-1-Space-Presentation-Handouts.pdf
Section sources →